APGE

APGE

USD

Apogee Therapeutics Inc. Common Stock

$54.710-0.290 (-0.527%)

即時價格

Healthcare
生物科技
美國

價格圖表

Loading Chart...

關鍵指標

市場指標
公司基本面
交易統計

市場指標

開盤

$55.000

最高

$55.930

最低

$52.340

交易量

1.04M

公司基本面

市值

3.7B

行業

生物科技

國家

United States

交易統計

平均交易量

0.66M

交易所

NGM

貨幣

USD

52週範圍

最低 $26.2當前 $54.710最高 $63.5

相關新聞

GlobeNewswire

Apogee Therapeutics Provides Pipeline Progress and Reports Third Quarter 2025 Financial Results

Pipeline programs continue to advance, with four clinical data readouts anticipated in 2026; APG777 trial readout timelines accelerated, with Phase 1b in asthma and APEX 52-week Part A data in AD anticipated in Q1 2026,

查看更多
Apogee Therapeutics Provides Pipeline Progress and Reports Third Quarter 2025 Financial Results
Analyst Upgrades

Craig-Hallum Initiates Coverage On Apogee Therapeutics with Buy Rating, Announces Price Target of $109

Craig-Hallum analyst Adam Vogel initiates coverage on Apogee Therapeutics with a Buy rating and announces Price Target of $109.

查看更多
Craig-Hallum Initiates Coverage On Apogee Therapeutics with Buy Rating, Announces Price Target of $109
Analyst Upgrades

RBC Capital Maintains Outperform on Apogee Therapeutics, Raises Price Target to $70

RBC Capital analyst Brian Abrahams maintains Apogee Therapeutics with a Outperform and raises the price target from $60 to $70.

查看更多
RBC Capital Maintains Outperform on Apogee Therapeutics, Raises Price Target to $70
GlobeNewswire

Apogee Therapeutics to Participate in Upcoming Conferences

SAN FRANCISCO and BOSTON, Nov. 03, 2025 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc., (NASDAQ:APGE), today announced that members of management will participate at the following investor conferences. Guggenheim 2nd

查看更多
Apogee Therapeutics to Participate in Upcoming Conferences
Analyst Upgrades

Mizuho Initiates Coverage On Apogee Therapeutics with Outperform Rating, Announces Price Target of $105

Mizuho analyst Joseph Catanzaro initiates coverage on Apogee Therapeutics with a Outperform rating and announces Price Target of $105.

查看更多
Mizuho Initiates Coverage On Apogee Therapeutics with Outperform Rating, Announces Price Target of $105